A Case of Malignant Lymphoma that Healed Completely after Oral Administrations of 4-Hydroxybenzaldehyde

2018 ◽  
Vol 1 (1) ◽  
pp. 01-02
Keyword(s):  
Cancer Patient ◽  
Malignant Lymphoma ◽  
Large Dose ◽  
Side Effect ◽  
Small Dose ◽  
Severe Hemorrhage ◽  
Tumor Agent

In 1969, Mutsuyuki Kochi [1, 2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and patent it. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemias. Consequently, those who have these diseases can receive a considerably large dose of the medicine.

Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient

2011 ◽  
Vol 29 (2) ◽  
pp. 1017-1019 ◽  
Author(s):  
Veli Berk ◽  
Sevda Ismailogullari ◽  
Halil Donmez ◽  
Halit Karaca ◽  
Mevlude Inanc ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patient ◽  
Side Effect ◽  
Colon Cancer Patient ◽  
Generalized Seizures

scholarly journals Family’s experience in Caring of Cancer Patient undergoing Oral Chemotherapy : A Study Phenomenology

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Nurul Huda ◽  
Erwin Erwin ◽  
Eka Febriyanti
Keyword(s):  
Health Care ◽  
Side Effects ◽  
Cancer Patient ◽  
Side Effect ◽  
Oral Chemotherapy ◽  
Family Experience ◽  
Home Setting ◽  
Manage Care ◽  
Improve Compliance ◽  
Chemotherapy Agents

ABSTRACTThe use of Oral Chemotherapy is increasing nowadays. Family who directly involve in caring the patient should be aware of the side effect and how to handle this agent safely. Phenomenology approach of qualitative study was conducted to get illustration regarding family experience in managing care of patient receiving oral chemotherapy. Data was collected by semi structured interviewed. Study gathered from 10 participants who meet criteria. The current study showed that three temathic item related to how they manage care to their family’s member. Those are 1) Lack of knolwedge about oral chemotherapy, 2) Confusing in handling safe oral chemotherapy and 3) lack of ability in caring patients when  side effect appeared and following adherence. These three things are considered lacked by the patients.  Therefore, health care professional especially nurses are expected to give more education and attention about administering oral chemotherapy agents, safe handling, adherence and managing side effects  both of in clinical and home setting. Multi-component interventions that include education, equipment, and technology can improve compliance with oral chemotherapy and will help families to secure and provide the appropriate affection to them.ABSTRAKPenggunaan kemoterapi oral semakin meningkat saat ini. Keluarga yang secara langsung terlibat dalam merawat pasien harus menyadari efek samping dan cara menangani terapi ini dengan aman. Penelitian kualitatif dengan pendekatan fenomenologi dilakukan untuk mendapatkan gambaran mengenai pengalaman keluarga dalam mengelola perawatan pasien yang menerima kemoterapi oral. Data dikumpulkan secara semi terstruktur melalui wawancara. Penelitian ini terdiri dari 10 partisipan keluarga yang memenuhi kriteria inklusi. Hasil penelitian menunjukkan  terdapat tiga tema terkait bagaimana keluarga merawat pasien dengan oral chemotherapy di rumah. Ketiga tema tersebut adalah 1) kurangnya pengetahuan keluarga tentang oral kemoterapi, 2) kebingungan keluarga dalam penanganan keamanan oral chemotherapy dan 3) ketidakmampuan keluarga dalam menangani efek samping dan menjaga kepatuhan. Ketiga hal ini dianggap masih belum bisa dilakukan oleh keluarga dan membutuhkan bimbingan serta informasi dari petugas kesehatan. Oleh karena itu, petugas kesehatan professional terutama perawat diharapkan dapat memberikan edukasi dan perhatian yang lebih kepada keluarga  tentang bagaimana pemberian kemoterapi oral yang baik, penanganan yang aman serta peningkatan kepatuhan dalam menjalani perawatan. Memberikan intervensi multikomponen yang mencakup pendidikan, peralatan pendukung, dan teknologi dipercayai dapat meningkatkan kemampuan dalam perawatan dan kepatuhan dalam menjalani kemoterapi oral, sehingga  dapat membantu keluarga untuk memberikan rasa aman dan kasih sayang yang kepada pasien.

scholarly journals Effects of Curculigo orchioides total glucosides in mouse perimenopause model of related organization and organs morphology

2016 ◽  
Vol 11 ◽  
pp. S72-S81 ◽  
Author(s):  
Cao Shan ◽  
Tian Shuo ◽  
Bai Ming ◽  
Liu Shaoyan ◽  
Jia Jiaojiao ◽  
...  
Keyword(s):  
Large Dose ◽  
Small Dose ◽  
Pathological Changes ◽  
Model Group ◽  
Mouse Uterus ◽  
Curculigo Orchioides ◽  
Soybean Isoflavone ◽  
Improvement Effect ◽  
Good Improvement ◽  
Different Doses

The purpose of this study was to examine the effects of Curculigo orchioides total glucosides in mouse perimenopause model. The castrated mice were treated with different doses of soybean isoflavone soft capsule, Gengnian’an, C. rhizome total glycoside. Hypothalamus, thymus, spleen and uterus were collected and then fixed in 10% formaldehyde, HE staining, to observe the pathological changes of morphology. The results indicate that compared with the model group, soybean isoflavone soft capsule, gengnianan capsule and big, medium, small dose of C. rhizome total glycoside group could significantly improved the pathological changes in mouse uterus, hypothalamic, thickening of the thymic cortex and significantly increased the number of lymphocytes in the cortex, increased the volume of splenic nodule (p<0.01), in which the effect of large dose of C. orchioides total glycosides group was the best. In conclusion, C. orchioides total glucosides in mice caused by perimenopausal pathological changes of uterine, hypothalamus, spleen and other organs have good improvement effect. 

Effects of Shenqihuafen Tablets on Immune Function in Normal Mices

2014 ◽  
Vol 926-930 ◽  
pp. 981-984
Author(s):  
Ming San Miao ◽  
Ti Sheng Cui ◽  
Bo Lin Cheng
Keyword(s):  
Immune Function ◽  
Large Dose ◽  
Small Dose ◽  
Abdominal Cavity ◽  
Plaque Formation ◽  
Macrophage Cell ◽  
Blank Group ◽  
High Doses ◽  
Different Doses ◽  
Medium Dose

Objective: observed the influence on the immune function of normal mices to study the Shenqihuafen tablets function characteristics of the lung tonifition and the spleen invigoration. Methods:administered different doses of Shenqihuafen tablets to normal mices ,determinated of the Percentage and index of macrophage cell in abdominal cavity. Results: compared with the blank group, large, medium dose Shenqihuafen tablets group showed significantly higher percentage of macrophage cell in abdominal cavity of mices (P < 0.01), large, medium and small dose of Shenqihuafen tablets group showed significantly higher index of macrophage cell in abdominal cavity of mices. High doses of Shenqihuafen tablets group promoted significantly the formation of hemolysin in mices (P < 0.01), large dose of Shenqihuafen group promote significantly hemolytic plaque formation in mices (P < 0.01). Conclusion: Shenqihuafen tablets increased significantly the immune of mices.

Pharmacodynamic Modeling of Muscle Relaxants

2002 ◽  
Vol 96 (3) ◽  
pp. 711-717 ◽  
Author(s):  
Matthias Paul ◽  
Dennis M. Fisher
Keyword(s):  
Large Dose ◽  
Small Dose ◽  
Muscle Relaxants ◽  
Pharmacodynamic Modeling ◽  
Parameter Estimates ◽  
Published Data ◽  
Bolus Administration ◽  
Complete Paralysis ◽  
Dosing Regimens ◽  
The Impact

Background Pharmacodynamic studies of muscle relaxants use different dosing regimens (such as administration by bolus vs. infusion and doses that produce complete vs. incomplete paralysis). The authors used published data to evaluate the effect of modeling assumptions on pharmacodynamic estimates. Methods The authors used a pharmacokinetic-pharmacodynamic dataset in which patients received cisatracurium, 75 or 300 microg/kg (1.5 or 6 x ED95), to generate plasma concentration (Cp) and twitch depression (effect) curves. They then evaluated the impact of the following: assuming that Cp decreased monotonically versus increasing initially before decreasing monotonically; misrecording effect data by 6 s or less; and doses targeting incomplete versus complete paralysis. Parameters evaluated were the steady state Cp depressing twitch tension 50% (C50) and the rate constant for equilibration between plasma and effect site concentrations (k(e0)). Results With the large dose, increasing the time at which Cp peaked from 0.0 to 1.5 min decreased C50 and increased k(e0) markedly; with the small dose, changes in both were small. Misrecording the timing of effect had a larger impact with the large dose compared with the small dose. Doses smaller than ED50 or those producing prolonged, complete twitch depression yielded biased and variable estimates. Conclusion The erroneous assumption that Cp decreases monotonically after bolus administration affects accuracy of pharmacodynamic estimates with doses producing rapid, complete twitch depression. Other errors (e.g., misrecording the time of drug administration) impact on pharmacodynamic estimates, particularly with large doses. The authors' findings suggest that investigators performing neuromuscular (and other) pharmacodynamic studies should carefully consider the impact of study design on their parameter estimates.

scholarly journals A novel network controllability algorithm to target personalized driver genes for discovering combinational drugs of individual cancer patient

2019 ◽  
Author(s):  
Wei-Feng Guo ◽  
Shao-Wu Zhang ◽  
Tao Zeng ◽  
Luonan Chen
Keyword(s):  
Cancer Patient ◽  
Side Effect ◽  
Target Genes ◽  
Driver Gene ◽  
Omics Data ◽  
Driver Genes ◽  
Data Set ◽  
Cancer Data ◽  
Personalized Risk ◽  
Network Controllability

AbstractTreating cancer in precision medicine, it is important to identify the personalized combinational drugs under consideration of the individual heterogeneity. Many bioinformatics tools for the personalized driver genes identification have presented promising clues in determining candidate personalized drug targets for the personalized drugs discovery. However, it has not been studied how to fill the gap between personalized driver genes identification and personalized combinational drugs discovery. In this work, we developed a novel algorithm of structure network Controllability-based Personalized driver Genes and combinational Drug identification (CPGD), aiming to mine the personalized driver genes and identify the combinational drugs of an individual cancer patient. On two benchmark cancer datasets, the performance of CPGD for predicting the clinical efficacious combinational drugs is superior to that of other state-of-the-art driver gene-focus algorithms in terms of precision accuracy. In particular, by quantifying and referring the relationships between target genes of pairwise combinatorial drugs and disease module genes on breast cancer data set, CPGD can significantly divide patients into the discriminative high-risk and low-risk groups for risk asessment in combination therapy. In addition, CPGD can further enhance cancer subtyping by providing computationally personalized side effect signatures for individual patients. Collectively, CPGD provided a new and effecient bioinformatics tool from structure network controllability perspective for discovering personalized combinational drugs with personalized side effect consideration, so as to effectively support personalized risk assessement and disease subtyping.SignificanceIt is quite challenging to predict personalized combinational drugs rather than patient-cohort‘s drugs based on cancer omics data. In this work, a novel structure network Controllability-based algorithm (CPGD) from feedback vertex sets control perspective was developed, for discovering efficacious combinational drugs of an individual cancer patient by targeting the personalized driver genes. The CPGD contains three methodological advances by exploring more precise mathematical models on high-throughput personalized multi-omics data. The first is that a proper network structure is constructed to characterize the gene regulatory mechanism of an individual patient. The second is that considering the weight information of network edges/relations improves the performance for predicting clinical efficacious combinational drugs compared with other drivers-focus methods. And the third is that proper evaluation metrics for personalized combinational drugs prioritization, personalized risk assessment and disease subtyping are designed when evaluating the performance of CPGD.

scholarly journals Is Tumorigenesis an Abiogenesis?

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Hugwil AV
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Cancer Patient ◽  
Side Effect ◽  
Image Transmission ◽  
Internal Image ◽  
Idiotypic Antibody

CLN-IgG (Pritumuab) was subjected to clinical trials aiming at regression of brain tumors. The mechanism underlying the dramatic recuperation of cancer patient was considered by means of augmentation of idiotypic antibody-mediated internal image transmission of the vimentin epitope-vipidam. Silencing of prionogenicity of vimentin by chaperonic antibody CLN-IgG was a pertinent modality to elongate cancer patient's senescence with little side effect.

Remifentanil-induced Postoperative Hyperalgesia and Its Prevention with Small-dose Ketamine

2005 ◽  
Vol 103 (1) ◽  
pp. 147-155 ◽  
Author(s):  
Vincent Joly ◽  
Philippe Richebe ◽  
Bruno Guignard ◽  
Dominique Fletcher ◽  
Pierre Maurette ◽  
...  
Keyword(s):  
Large Dose ◽  
Small Dose ◽  
Detection Threshold ◽  
Skin Closure ◽  
Cognitive Tests ◽  
Secondary Hyperalgesia ◽  
Healthy Human ◽  
Pain Scores ◽  
Human Volunteers ◽  
Quantitative Sensory Tests

Background Remifentanil-induced secondary hyperalgesia has been documented experimentally in both animals and healthy human volunteers, but never clinically. This study tested the hypotheses that increased pain sensitivity assessed by periincisional allodynia and hyperalgesia can occur after relatively large-dose intraoperative remifentanil and that small-dose ketamine prevents this hyperalgesia. Methods Seventy-five patients undergoing major abdominal surgery were randomly assigned to receive (1) intraoperative remifentanil at 0.05 microg x kg(-1) x min(-1) (small-dose remifentanil); (2) intraoperative remifentanil at 0.40 microg x kg(-1) x min(-1) (large-dose remifentanil); or (3) intraoperative remifentanil at 0.40 microg x kg(-1) x min(-1) and 0.5 mg/kg ketamine just after the induction, followed by an intraoperative infusion of 5 microg x kg(-1) x min(-1) until skin closure and then 2 microg x kg(-1) x min(-1) for 48 h (large-dose remifentanil-ketamine). Pain scores and morphine consumption were recorded for 48 postoperative hours. Quantitative sensory tests, peak expiratory flow measures, and cognitive tests were performed at 24 and 48 h. Results Hyperalgesia to von Frey hair stimulation adjacent to the surgical wound and morphine requirements were larger (P &lt; 0.05) and allodynia to von Frey hair stimulation was greater (P &lt; 0.01) in the large-dose remifentanil group compared with the other two groups, which were comparable. There were no significant differences in pain, pressure pain detection threshold with an algometer, peak flow, cognitive tests, or side effects. Conclusion A relatively large dose of intraoperative remifentanil triggers postoperative secondary hyperalgesia. Remifentanil-induced hyperalgesia was prevented by small-dose ketamine, implicating an N-methyl-d-aspartate pain-facilitator process.

Torsades de Pointes Caused by a Small Dose of Risperidone in a Terminally Ill Cancer Patient

2004 ◽  
Vol 45 (5) ◽  
pp. 450-451 ◽  
Author(s):  
Yo Tei ◽  
Tatsuya Morita ◽  
Satoshi Inoue ◽  
Haruo Miyata
Keyword(s):  
Cancer Patient ◽  
Small Dose ◽  
Terminally Ill ◽  
Torsades De Pointes
Sign in / Sign up

Export Citation Format

Share Document